Basophils unlimited

Basophils are the rarest granulocytes, representing less than 1% of peripheral blood leukocytes. During the 130 years that has passed since they were first described by Paul Ehrlich, they have been one of the most enigmatic inflammatory cells and their precise biological roles are still unclear. With their expression of the high-affinity IgE receptor (FceRI) and ability to release histamine upon IgE-mediated activation, basophils were long considered to be a distant, and possibly redundant, relative to tissue resident mast cells regarding promotion of allergic inflammation. During the last decade, however, new data have emerged, mainly from animal studies, pointing to previously unrecognized functions of basophils in health and diseases beyond allergy, such as autoimmunity and host defense [reviewed recently by Karasuyama et al. (1)]. These advances have been fostered by newly developed tools for in vivo functions of basophils in animal models using basophil-depleting antibodies and genetically engineered mice deficient only in basophils. One difficulty in basophil research has been, because of their rarity, to obtain sufficient numbers of basophils to perform cell-based studies, for example, to investigate signaling pathways and functional responses, and for models to screen for drug targets. In contrast to in vitro differentiation of mast cells, which gives a good yield with high cell purities, there are no protocols that provide corresponding pure cultures of basophils derived from stem cells, especially from mice. One human basophilic-like cell line, KU812 (2), has been used for some studies, but it has several limitations including a variable cell surface expression of FceRI and low degree of granulation (3). Because of this, in vitro studies on basophils have been largely limited to the costly and cumbersome isolation and purification of primary human basophils from whole blood or buffy coats. However, despite the value of data obtained from primary human basophils, given the recent advances in ascertaining the biological role of basophils in mice using in vivo models, there is a vital need for a technique that enables the generation of functional mouse basophils with a normal phenotype. In the current issue of Allergy, Gurzeler et al. (4) describe the generation of ‘near-unlimited’ numbers of mouse basophils using a genetic approach where myeloid progenitors are immortalized with the transcription factor Hoxb8 in the presence of IL-3 and tamoxifen (4-OHT). The expression of Hoxb8 is under the control of 4-OHT, which means that Hoxb8 is expressed when 4-OHT is present and the progenitor cells expand. To differentiate the magnified progenitors into basophils, 4-OHT was omitted from the cultures, and basophils were differentiated in the presence of IL-3 only. These basophils displayed the currently accepted characteristics of mouse basophils in that they expressed FceRI, CD123, CD88, and CD11b but not Kit, CCR3, or Gr-1. More importantly, however, Gurzeler et al. comprehensively studied, for the first time, the ability of these cells to release histamine and leukotriene C4, as well as the archetypal Th2-type cytokines IL-4 and IL-13, to IgE-dependent and IgE-independent stimulation. These observations suggest that basic mediator release characteristics of these mouse basophils broadly resemble those of their human basophil counterparts (Fig. 1). This technique now permits vital studies into the signal transduction and functional attributes of murine basophils, albeit under the caveat that genetic manipulation and in vitro culture may not fully represent the behavior of primary mouse basophils. However, given the impracticality of isolating sufficient numbers of these cells from mouse blood Gurzeler et al. have presented a highly useful tool in which to build on the findings obtained using in vivo models. Moreover, it will now be possible to study the functional properties of these cells side by side with primary human basophils which is vital in order to determine to what extent mouse basophils can truly be employed as a surrogate for primary human basophils in, for example, discovering new therapeutic targets for treating allergy and autoimmune diseases. Although obtaining large number of mouse basophils is now possible, it is important to stress the potential heterogeneity that exists between these cells and their human counterparts (Fig. 1). Despite their apparent similarities in being able to release a number of pro-allergic mediators to IgEdependent stimuli, there are some fundamental differences between mouse and human basophils which should not be overlooked (5). These include the effects of Fcc receptors, which are stimulatory in mouse but inhibitory in human basophils. In agreement with Gurzeler et al. (4), mouse